Clinical trial
A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic…
NCT00283634 · Millennium Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00283634 |
|---|---|
| Title | A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer |
| Official title | A Randomized, Non-comparative, Multicenter, Open-Label, Phase 2 Study of Tarceva™ (Erlotinib) Alone and of Tarceva Plus VELCADE* (Bortezomib) for Injection in Patients With Relapsed or Refractory, Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Collaborators | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | NSCLC |
| Intervention type | Drug |
| Interventions | erlotinib and bortezomib |
| Start date | Aug 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jan 30, 2006 |
| Last update posted | Feb 17, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: